Discovery & Development Europe 2025: Formulation & Drug Delivery Congress
July 1-2, 2025
Basel, Switzerland

Invited lecture:
Oral Delivery Of Peptide And Protein Drugs – Oral Delivery of GLP-1 Analogues

Prof. Dr. A. Bernkop-Schnürch
more...

8th European Cyclodextrin Conference
September 9-12, 2025
Milano, Italy

Invited lecture:
Thiolated Cyclodextrins in Drug Delivery

Prof. Dr. A. Bernkop-Schnürch
more...

Preclinical studies

Orientating cytotoxicity studies for formulation

ThioMatrix performes orientating cytotoxicity studies in order to evaluate the influence of auxiliary agents and excipients on the toxicological potential of your drug. These studies include:

• Ciliary beat frequency studies
  
  
• LDH assay
  
  
• MTT assay
  
  
• BrdU test
  
  
• Red blood cell lysis test

Development and validation of quantification methods

For in vivo studies with a new drug it is essential to establish an accurate and validated quantification method in order to be able to determine drug concentrations in compartments such as plasma or cerebrospinal fluid even in the picogram per ml range. ThioMatrix develops and validates such quantification methods and/or can assist you thereby.

In vivo studies

ThioMatrix designs and performs in vivo studies in small and large animals. Based on the results of such studies drug delivery systems can be optimised. ThioMartix is specialized on:

• tolerability studies
  
  
• dose finding studies
  
  
• pharmacokinetic studies
  
  
• biofeedback studies

Preparation of Common Technical Documents (CTDs) / Quality Overall Summaries (QOSs)

ThioMatrix has technical writing expertise and experience in all major therapeutic areas. We can help organize and prepare CTD and QOS in strict accordance with EU/ICH guidelines and regulations. In addition to traditional paper documents, we provide e-submission services.

Clinical studies

Orientating studies in humans

ThioMatrix organizes, designs and coordinates orientating studies in humans. In comparison to phase I-III clinical trials such orientating studies are more cost-effective in order to provide a proof of concept and/or to obtain data on which further improvements of the drug delivery system can be done.

Phase I-IV clinical trials

ThioMatrix works in conjunction with various CROs for clinical trials. ThioMatrix can therefore coordinate and/or assist projects from first orientating in vitro studies, through the resulting design of the delivery system, preclinical and clinical studies to final approval.

Thiomatrix joined the EU-project TENTACLE (101191747) focusing on the use of thiomers for in situ bioprinting.
more....